



From Drug Carriers to Vaccine Adjuvants in Malaria

Guest Editors:

Prof. Dr. Xavier Fernández-Busquets

Barcelona Institute for Global Health (ISGlobal), and Institute for Bioengineering of Catalonia (IBEC), Centre Esther Koplowitz, Planta 1, ISGlobal, Rosselló 149-153, ES08036 Barcelona, Spain

Dr. Livia Neves Borgheti-Cardoso

Barcelona Institute for Global Health (ISGlobal), and Institute for Bioengineering of Catalonia (IBEC), Centre Esther Koplowitz, planta 1, ISGlobal, Rosselló 149-153, ES08036 Barcelona, Spain

Deadline for manuscript submissions:

closed (29 June 2019)

Message from the Guest Editors

Despite the undeniable importance of malaria elimination on the global research agenda, current vaccines in development do not offer prospects of complete protection, and the available front-line drugs are rapidly losing efficacy, with resistance already evolved to the first-line drug artemisinin. As a result, since 2014 the malaria incidence and mortality decline have stalled. Thus, alternative strategies working through radically new mechanisms are urgently needed.

Because malaria pathophysiology is so complex, and the disease is so widespread, it is generally accepted that to achieve eradication a combination of weapons will be needed. These include the improvement of existing approaches and the development of new ones, with drug therapy and vaccination remaining the mainstays of treatment and prevention, and pharmaceutical nanotechnology being a potentially essential tool in the future fight against malaria. Encapsulation of drugs in targeted nanovectors is a rapidly growing area with clear applicability to infectious disease treatment, and malaria vaccine adjuvants based on antigen binding to nanoparticles will be an essential asset for future prophylactic strategies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma